Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

MMQCI releases FilmArray tropical fever quality control

June 2025—Maine Molecular Quality Controls announced the release of the Film­Array TF control panel, for users of the FDA-cleared BioFire FilmArray tropical fever panel. The multiplexed control is intended for use as an external positive and negative assayed quality control to monitor the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of viral, bacterial, and parasitic pathogens. The kit includes six 200-μL positive controls and six 200-μL negative controls.

Labcorp acquires assets of NMHS ambulatory outreach lab business

June 2025—Labcorp and North Mississippi Health Services announced that Labcorp has completed its acquisition of North Mississippi Health Services’ ambulatory outreach laboratory business and is now a referral laboratory for NMHS’ seven hospitals and clinic laboratories. In addition, Labcorp will open three patient service centers in Tupelo, West Point, and Amory by midyear to increase availability of laboratory services in North Mississippi.

FDA clears Liaison Plex Gram-negative blood culture assay

June 2025—Diasorin announced it has received FDA 510(k) clearance for the Liaison Plex Gram-negative blood culture assay, the second of the company’s three multiplex molecular panels for blood culture pathogen identification on the Liaison Plex. The assay is designed to identify 27 targets—19 Gram-negative bacteria and eight relevant resistance gene targets, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Acinetobacter species, Citrobacter species, Enterobacter species, and Proteus species. Results are available about two hours after a Gram stain.

Visby gets clearance, CLIA waiver for POC respiratory test

June 2025—Visby Medical announced it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its point-of-care Medical Respiratory Health test. The PCR test detects and differentiates between upper respiratory infections caused by influenza A and B and SARS-CoV-2 and provides results in less than 30 minutes.

Mayo Clinic, Kyan collaborate to expand access to cancer testing

June 2025—Mayo Clinic Laboratories and Kyan Technologies announced a collaboration to validate and provide Kyan’s Optim.AI across the United States. Optim.AI is an ex vivo drug sensitivity platform that combines small data AI and biological experiments. It provides insights into therapies for cancer patients and delivers efficiencies for cancer drug development. Mayo Clinic Labs will provide testing for physicians and researchers to support clinical and research decision-making for better treatment options.

Thermo Fisher launches centrifuges with GreenCool technology

June 2025—Thermo Fisher Scientific introduced new lines of floor-model centrifuges that feature natural refrigerant cooling systems compliant with European Union and U.S. Environmental Protection Agency fluorinated gas regulations. The Thermo Scientific Cryofuge, Bios, and Lynx centrifuges feature the company’s GreenCool technology, a next-generation natural refrigerant cooling system with a global warming potential of 1. Each model provides a reduction in energy consumption of up to 15 percent when compared with previous models.

StatLab adds new U.S. manufacturing capabilities

June 2025—StatLab Medical Products announced that it is vertically integrating the production of containers and lids at its facility in Arlington, Tex., where the company currently produces nearly 100 million prefills annually, and will begin blow-molding gallon bottles in Q2. StatLab says it will also absorb any tariff-related fees associated with products manufactured in its European facilities when selling directly to U.S. laboratories. These products include PiSmart cassette and slide printers, KT microscope slides, and KT coverglass.

IDT introduces xGen hybridization, wash kit v3

June 2025—Integrated DNA Technologies unveiled its xGen Hybridization and Wash version 3 kit. The kit features a high-throughput workflow that eliminates heated buffers and reduces hands-on time by 20 percent. The one-hour hybridization step delivers high-quality results and enables users to get from sample to sequencer in one day. The kit supports library inputs as low as 100 ng and pairs with xGen predesigned or custom Hyb panels and xGen Blocking Oligos.

Thermo Fisher launches NGS hybrid capture assay

June 2025—Thermo Fisher Scientific has introduced the One Lambda HybriType HLA Plus Typing Flex kit, a next-generation sequencing hybrid capture assay featuring a probe-based design that optimizes read balance and uniformity, potentially mitigating allele dropout. The assay is designed to provide flexibility in testing configuration and coverage, supporting human leukocyte antigen class I and II genotyping analysis across various sample types, including whole blood and buccal swabs. It has a turnaround time of less than 5.5 hours, and the hands-on time is less than 2.5 hours. Data for the assay are analyzed using the company’s Type­Stream Visual NGS analysis software. The kit is for research use only.

MARKETPLACE

TRENDING